March 11 (Reuters) – Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement in muscle function and a clean safety profile.
The company was testing the treatment, called RGX-202, in boys aged 1 to 12.
The company said children who received the therapy showed better performance at one year across standard tests used to track how quickly Duchenne progresses, such as how fast they can stand up or climb stairs.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
